[go: up one dir, main page]

MX2023012851A - Métodos de tratamiento y seguimiento de la enfermedad de parkinson. - Google Patents

Métodos de tratamiento y seguimiento de la enfermedad de parkinson.

Info

Publication number
MX2023012851A
MX2023012851A MX2023012851A MX2023012851A MX2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A
Authority
MX
Mexico
Prior art keywords
methods
disease
monitoring
treatment
parkinson
Prior art date
Application number
MX2023012851A
Other languages
English (en)
Inventor
Sarah Huntwork-Rodriguez
Danna L Jennings
Vinay M Daryani
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2023012851A publication Critical patent/MX2023012851A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente descripción se refiere a métodos para tratar la enfermedad de Parkinson en un sujeto con un compuesto proporcionado en el presente documento, composiciones farmacéuticas que comprenden el compuesto, así como métodos para monitorear la respuesta del sujeto al tratamiento.
MX2023012851A 2021-04-30 2022-04-29 Métodos de tratamiento y seguimiento de la enfermedad de parkinson. MX2023012851A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182207P 2021-04-30 2021-04-30
PCT/US2022/026898 WO2022232487A1 (en) 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease

Publications (1)

Publication Number Publication Date
MX2023012851A true MX2023012851A (es) 2024-03-19

Family

ID=83847331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012851A MX2023012851A (es) 2021-04-30 2022-04-29 Métodos de tratamiento y seguimiento de la enfermedad de parkinson.

Country Status (9)

Country Link
US (1) US20240207266A1 (es)
EP (1) EP4329763A4 (es)
JP (1) JP2024515885A (es)
CN (1) CN117769422A (es)
AU (1) AU2022267325A1 (es)
CA (1) CA3217230A1 (es)
MX (1) MX2023012851A (es)
TW (1) TW202308635A (es)
WO (1) WO2022232487A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968373A (zh) * 2023-09-07 2025-05-09 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
CN121226329A (zh) * 2024-06-28 2025-12-30 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物
CN119119035B (zh) * 2024-08-30 2025-11-04 中山大学 一种ripk1激酶靶点抑制剂及其制备方法与应用
CN118878521B (zh) * 2024-09-26 2025-02-14 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027117B1 (pt) * 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
KR102553188B1 (ko) * 2016-06-16 2023-07-11 데날리 테라퓨틱스 인크. 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Also Published As

Publication number Publication date
CN117769422A (zh) 2024-03-26
US20240207266A1 (en) 2024-06-27
TW202308635A (zh) 2023-03-01
JP2024515885A (ja) 2024-04-10
WO2022232487A1 (en) 2022-11-03
AU2022267325A1 (en) 2023-11-16
CA3217230A1 (en) 2022-11-03
EP4329763A1 (en) 2024-03-06
EP4329763A4 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
MX2023012851A (es) Métodos de tratamiento y seguimiento de la enfermedad de parkinson.
NI201800124A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CL2019003800A1 (es) Métodos para tratar la enfermedad de huntington.
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
CR11723A (es) Agente para tratar enfermedad
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CO2022011388A2 (es) Inhibidores heterocíclicos de pad4
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
ZA202000680B (en) Obinutuzumab treatment of a dlbcl patient subgroup
MX2017009325A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2016007803A (es) Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
ECSP13012603A (es) Nueva formulacion del cetp(1)
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca